KRAS and neoplasm: Furthermore, antigenic discontinuum owing to the oncogenic mutations (including those in KRAS) or chromosome rearrangements (such as BCR-ABL1) can induce a non-destructive immune response that is aberrantly considered as tumor immunity [67–69].